DAPK1 promoter hypermethylaiton in brain metastases and peripheral blood

Neoplasma

Volumn 54, Issue 2, 2007, Pages 123-126

  Martinez Glez, V ^a   Franco Hernandez, C ^a   Gonzalez Gomez, P ^a   Isla, A ^a   De Campos, J M ^b   Vaquero, J ^c   Gutierrez, M ^a   Casartelli, C ^d   Rey, J A ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b HOSPITAL UNIVERSITARIO RÍO HORTEGA   (Spain)

^c HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^d UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Brain metastases; DAPK1; Promoter hypermethylation

Indexed keywords

APOPTOSIS; ARTICLE; BLOOD; BLOOD SAMPLING; BRAIN DEVELOPMENT; BRAIN METASTASIS; CANCER DIAGNOSIS; CLINICAL ARTICLE; CPG ISLAND; DAPK1 GENE; GENE EXPRESSION; GENE SEQUENCE; GENE SILENCING; HUMAN; HUMAN TISSUE; METHYLATION; PROGNOSIS; PROMOTER REGION; SOLID TUMOR; TUMOR CELL; BRAIN TUMOR; DNA METHYLATION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; METASTASIS;

ANTINEOPLASTIC ANTIMETABOLITE; APOPTOSIS REGULATORY PROTEIN; AZACITIDINE; DEATH ASSOCIATED PROTEIN KINASE; DNA; PROTEIN KINASE (CALCIUM,CALMODULIN); TUMOR MARKER;

ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS REGULATORY PROTEINS; AZACITIDINE; BRAIN NEOPLASMS; CA(2+)-CALMODULIN DEPENDENT PROTEIN KINASE; CPG ISLANDS; DNA METHYLATION; DNA, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; PROMOTER REGIONS (GENETICS); TUMOR MARKERS, BIOLOGICAL;

EID: 34347237289     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. NORDEN AD, WEN PY, KESARI S. Brain metastases. Curr Opin Neurol. 2005; 18: 654-661.
2. PETERSEN I, HIDALGO A, PETERSEN S, SCHLUNS K, SCHEWE C, PACYNA-GENGELBACH M, GOEZE A, KREBBER B, KNOSEL T, KAUFMAN O, SZYMAS J, von DEIMLING A. Chromosomal imbalances in brain metastases of solid tumors. Brain Pathol. 2000;10: 395-401. (Pubitemid 30431292)
3. WEBER GF, ASHKAR S. Stress response genes: the genes that make cancer metastasize. J Mol Med. 2000; 78:404-408.
4. LLOYD BH, PLATT-HIGGINS A, RUDLAND PS, BARRACLOUGHB R. Human S100A4 (p9Ka) induces the metastatic phenotype upon benign tumour cells. Oncogene. 1998; 17: 465-473.
5. ROETGER A, MERSCHJANN A, DITTMAR T, JACKISCH C, BARNEKOW A, BRANDT B. Selection of potentially metastatic subpopulations expressing c-erbB-2 from breast cancer tissue by use of an extravasation model. Am J Pathol. 1998; 153: 1797-1806.
6. YOKOTA J, NISHIOKA M, TANI M, KOHNO T. Genetic alterations responsible for metastatic phenotypes of lung cancer cells. Clin Exp Metastasis. 2003; 20: 189-193.
7. DEISS LP, FEINSTEIN E, BERISSI H, COHEN O, KIMCHI A. Identification of a novel serine/threonine kinase and a novel 15-kD protein as potential mediators of the gamma interferon-induced cell death. Genes Dev. 1995; 9: 15-30.
8. COHEN O, FEINSTEIN E, KIMCHI A. DAP-kinase is a Ca2+/calmodulin- dependent, cytoskeletal-associated protein kinase, with cell death-inducing functions that depend on its catalytic activity. EMBO J. 1997; 16: 998-1008.
9. COHEN O, INBAL B, KISSIL JL, RAVEH T, BERISSI H, SPIVAK-KROIZAMAN T, FEINSTEIN E, KIMCHI A. DAPkinase participates in TNF-alpha- and Fas-induced apoptosis and its function requires the death domain. J Cell Biol. 1999; 146: 141-148.
10. INBAL B, COHEN O, POLAK-CHARCON S, KOPOLOVIC J, VADAI E, EISENBACH L, KIMCHI A. DAP kinase links the control of apoptosis to metastasis. Nature. 1997; 390: 180-184.
11. JONES PA, LAIRD PW. Cancer epigenetics comes of age. Nat Genet. 1999 Feb;21(2):163-167
12. ESTELLER M, HERMAN JG. Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours. J Pathol. 2002; 196: 1-7. (Pubitemid 34071572)
13. TANG X, KHURI FR, LEE JJ, KEMP BL, LIU D, HONG WK, MAO L. Hypermethylation of the death-associated protein (DAP) kinase promoter and aggressiveness in stage I non-small-cell lung cancer. J Natl Cancer Inst. 2000; 92 :1511-1516.
14. KATZENELLENBOGEN RA, BAYLIN SB, HERMAN JG. Hypermethylation of the DAP-kinase CpG island is a common alteration in B-cell malignancies. Blood. 1999; 93: 4347-4353.
15. NG MH, TO KW, LO KW, CHAN S, TSANG KS, CHENG SH, NG HK. Frequent death-associated protein kinase promoter hypermethylation in multiple myeloma. Clin Cancer Res. 2001; 7: 1724-1729.
16. JONES PA, BAYLIN SB. The fundamentel role of epigenetic events in cancer. Nature Rev Genetics 2002; 3: 415-428.
17. GONZALEZ-GOMEZ P, BELLO MJ, ALONSO ME, AMIÑOSO C, LOPEZ-MARIN I, DE CAMPOS JM, ISLA A, GUTIERREZ M, REY JA. Promoter methylation status of multiple genes in brain metastases of solid tumors. Int J Mol Med. 2004; 13 :93-98.
18. NELSON JS, VON DEIMLING A, PETERSEN I, JANZEN R-C. Metastatic tumours of the CNS. In: Pathology and Genetics of Tumours of the Nervous System. World Health Organization Classification of Tumours. Kleihues P and Cavenee WK (eds). IARC Press, Lyon, pp250-253, 2000.
19. REY JA, BELLO MJ, JIMENEZ-LARA AM, VAQUERO J, KUSAK ME, DE CAMPOS JM, SARASA JL, PESTAŃA A. Loss of heterozygosity for distal markers on 22q in human gliomas. Int J Cancer. 1992; 51 :703-706.
20. HERMAN JG, GRAFF JR, MYOHANEN S, NELKIN BD, BAYLIN SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A. 1996; 93: 9821-9826.
21. ZCHBAUER-MULLER S, FONG KM, VIRMANI AK, GERADTS J, GAZDAR AF, MINNA JD. Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res. 2001; 61: 249-255. (Pubitemid 32095725)
22. REDDY AN, JIANG WW, KIM M, BENNOIT N, TAYLOR R, CLINGER J, SIDRANSKY D, CALIFANO JA. Death-associated protein kinase promoter hypermethylation in normal human lymphocytes. Cancer Res. 2003; 63: 7694-7698. (Pubitemid 37466698)
23. LAIRD PW. The power and promise of DNA methylation markers. Nature Rev Cancer 2003; 3: 253-266.